NKGen Biotech Company Description

NKGen Biotech, Inc., a clinical-stage biotechnology company, develops cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells.

Its lead products include SNK01, an autologous NK cell therapy candidate for the treatment of neurodegenerative diseases, and SNK02, an allogeneic NK cell therapy for refractory solid tumors.

The company has a license agreement with NKMAX for its NK cell program. The company has a strategic partnership with HekaBio K.K. for the development of the company's autologous NK cell therapy, troculeucel, in Japan.

The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.

NKGen Biotech, Inc.

Country	United States
Founded	2017
Industry	Biotechnology
Sector	Healthcare
Employees	63
CEO	Paul Y. Song

Contact Details

Address: 3001 Daimler Street Santa Ana, Delaware 92705 United States
Phone	949-396-6830
Website	nkgenbiotech.com

Stock Details

Ticker Symbol	NKGN
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US65488A1016
SIC Code	2836

Key Executives

Name	Position
Dr. Paul Y. Song M.D.	Chief Executive Officer and Chairman
Dr. Yong Man Kim Ph.D.	Chief Scientific Officer
James A. Graf	Interim Chief Financial Officer
Yoonmi Kang	SVice President of Technical Ops and Development
Irene Chang	SVice President, Human Resources and Corporate Culture
Denise A. Chua CLS, MBA, MT (ASCP)	SVice President of Corporate Affairs
Ryan Park C.F.A.	Executive Vice President of FP&A, Corporate Planning and Strategy